Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of “Hold” by Analysts

Shares of Replimune Group, Inc. (NASDAQ:REPL) have been assigned a consensus recommendation of “Hold” from the ten ratings firms that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, two have issued a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $10.00.

A number of brokerages have issued reports on REPL. Piper Sandler upped their target price on Replimune Group from $13.00 to $14.00 and gave the stock an “overweight” rating in a research report on Thursday, February 5th. Wedbush raised their target price on shares of Replimune Group from $18.00 to $19.00 and gave the company an “outperform” rating in a research note on Wednesday, February 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Replimune Group in a research report on Monday, December 29th.

Insider Transactions at Replimune Group

In other Replimune Group news, CEO Sushil Patel sold 10,000 shares of Replimune Group stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $11.13, for a total value of $111,300.00. Following the transaction, the chief executive officer directly owned 333,576 shares of the company’s stock, valued at $3,712,700.88. The trade was a 2.91% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Kapil Dhingra sold 3,169 shares of the stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $10.40, for a total value of $32,957.60. The SEC filing for this sale provides additional information. Insiders own 5.20% of the company’s stock.

Hedge Funds Weigh In On Replimune Group

Large investors have recently bought and sold shares of the stock. Saturn V Capital Management LP bought a new stake in shares of Replimune Group in the second quarter valued at about $1,198,000. Readystate Asset Management LP raised its stake in Replimune Group by 1,296.2% during the third quarter. Readystate Asset Management LP now owns 2,621,012 shares of the company’s stock worth $10,982,000 after acquiring an additional 2,433,292 shares in the last quarter. Erste Asset Management GmbH increased its position in shares of Replimune Group by 13,597.5% during the 3rd quarter. Erste Asset Management GmbH now owns 1,630,000 shares of the company’s stock worth $7,074,000 after purchasing an additional 1,618,100 shares in the last quarter. Squarepoint Ops LLC raised its stake in shares of Replimune Group by 394.0% in the second quarter. Squarepoint Ops LLC now owns 67,929 shares of the company’s stock valued at $631,000 after acquiring an additional 54,178 shares during the last quarter. Finally, Nan Fung Trinity HK Ltd. bought a new position in Replimune Group in the 2nd quarter valued at $4,325,000. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Trading Down 0.5%

Replimune Group stock opened at $7.65 on Monday. Replimune Group has a one year low of $2.68 and a one year high of $13.24. The company’s fifty day moving average price is $8.15 and its two-hundred day moving average price is $7.53. The company has a debt-to-equity ratio of 0.33, a current ratio of 5.60 and a quick ratio of 5.60. The company has a market capitalization of $631.66 million, a price-to-earnings ratio of -2.22 and a beta of 0.72.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Tuesday, February 3rd. The company reported ($0.77) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.08. On average, analysts forecast that Replimune Group will post -2.97 earnings per share for the current fiscal year.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.